Cellectis S.A.

Cellectis S.A. is a clinical stage biotechnology company that develops therapies based on gene-editing technology. Its primary focus is on allogeneic chimeric antigen receptor (CAR) T-cell product candidates for immuno-oncology, as well as gene therapy candidates for other therapeutic indications. Key product candidates include lasme-cel (evaluated in the BALLI-01 trial for relapsed/refractory acute lymphoblastic leukemia) and eti-cel (studied in the NatHaLi-01 trial for relapsed/refractory B-cell non-Hodgkin lymphoma). The company also has programs targeting large B-cell lymphoma (ALPHA3), advanced or metastatic clear cell renal cell carcinoma (TRAVERSE), and unresectable or metastatic melanoma.

Cellectis S.A. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CLLS. Its shares trade in US dollars (USD), making it accessible to investors in the United States and globally. The company is headquartered in Paris, France, but its listing on a US exchange allows it to reach a broader investor base.

Cellectis S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biotechnology company, it focuses on developing innovative gene-edited cell therapies, particularly allogeneic CAR T-cell products for cancer treatment. Its work involves cutting-edge genetic engineering to create off-the-shelf immunotherapies, which distinguishes it from traditional biotech firms that may focus on small molecules or biologics.

Cellectis S.A. is headquartered in Paris, France, and was founded in 1999. While its primary operations are based in France, the company serves a global market through its clinical trials and potential future therapies. Its product candidates target cancers such as acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, large B-cell lymphoma, renal cell carcinoma, and melanoma, indicating a focus on patients worldwide, particularly in regions with advanced healthcare systems.

Cellectis' pipeline includes several allogeneic CAR T-cell and gene therapy candidates. BALLI-01 evaluates lasme-cel in patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). NatHaLi-01 studies eti-cel for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). ALPHA3 targets large B-cell lymphoma (LBCL), and TRAVERSE is for advanced or metastatic clear cell renal cell carcinoma (RCC). Additionally, the company has a program for unresectable or metastatic melanoma. These candidates are in various stages of clinical development, reflecting the company's focus on addressing unmet medical needs in oncology.